. Author manuscript; available in PMC: 2010 Jun 4.

Published in final edited form as: J Am Stat Assoc. 2008 Dec 1;103(484):1392–1404. doi: 10.1198/016214508000000706

Table 3.

Characteristics of those with and without a study endpoint

	No Biopsy (R = 0) (N=5823)	Biopsy (R = 1) (N=10168)	P-value^a
Finasteride Arm	3015 (51.8%)	4951 (48.7%)	0.0002
Baseline PSA	1.0 (0.6, 1.7)^b	1.1 (0.7, 1.8)	< 0.0001
Baseline Age	63 (58, 67)	62 (58, 66)	0.0004
Race			< 0.0001
White	5310 (91.2%)	9471 (93.1%)
African American	242 (4.2%)	346 (3.4%)
Other	271 (4.7%)	351 (3.5%)
Family History of Prostate Cancer	785 (13.5%)	1695 (16.7%)	< 0.0001
Referred to Biopsy because of PSA	69 (1.2%)	802 (7.9%)	< 0.0001
Referred to Biopsy because of DRE	83 (1.4%)	831 (8.2%)	< 0.0001
Prior Negative Biopsy	477 (8.2%)	1348 (13.3%)	< 0.0001

Chi-square test for categorical variables, Wilcoxon rank sum test for continuous covariates (baseline PSA and age).

Median (1st quartile, 3rd quartile) reported for continuous covariates.